Why would a new immunotherapy approach be cause for researchers to reconsider Type 1 diabetes and its treatment? Perhaps a novel modified synthetic peptide-based technology platform known as Imotopes™ could pave the path for new classes of therapies that block...
Diabetes Type 1
Category
Beyond Type 1 and JDRF Come Together to Drive Greater Patient Trust, Engagement & Research Participation
Beyond Type 1 has partnered with JDRF—the world’s leading nonprofit funder of Type 1 diabetes (T1D) research—to educate the T1D community and the general public about current scientific developments, including the path to a cure for the chronic autoimmune...
Development of ‘Mini-Insulin’ and the Implications for A Superior, Faster-Acting Human Insulin for Type 1 Diabetes Patients
University of Utah researchers are part of an international team, including Danes and Australians, that have developed the world’s smallest, fully functional version of the insulin hormone based on venom from the predatory cone snail. It’s been almost a hundred years...
Univ. of Virginia Center for Public Health Genomics’ Investigator Pursues Simple Genetic Test for Type 1 Diabetes
Researchers at the Center for Public Health Genomics at the University of Virginia (Charlottesville) have developed a test that they think could predict the risk of type 1 diabetes. This would be a huge deal—preventing the situation where children are hospitalized in...
Research Led by City of Hope’s Bart O. Roep, Ph.D., Advances Personalized Medicine for Children With Type 1 Diabetes
As science continues to advance the understanding of how diseases like cancer and diabetes operate in the human body, the models for treatment have increasingly moved away from one-size-fits-all approaches and toward more individualized therapies. For example, City of...
PERL Study Results Show Uric Acid Has No Impact on Diabetic Kidney Disease
Diabetic kidney disease (DKD) remains one of the most intractable complications of diabetes. Progress has been made using glycemic and blood pressure control, but the search continues for improved treatments for the estimated one in four adults with diabetes who has...
Cambridge, MA-based Pandion Therapeutics Inks $795m Deal with Astellas Targeting Pancreas Immunomodulators
Cambridge, MA-based Pandion Therapeutics inked a license and collaboration deal worth up to $795 million with Japanese-based Astellas Pharma to research, develop and commercialize locally acting immunomodulators for autoimmune diseases of the pancreas. Pandion brings...
A Trial for Kids at Risk of Type 1 Diabetes was Scaled Back, Leaving Families in Limbo
At 19 years old, Sarah Hornak was diagnosed with Type 1 diabetes. It has been nearly 15 years since she learned she has the disease, a condition in which the body's immune cells attack the pancreas, the gland that regulates blood glucose levels by secreting insulin....
Better Technology Means Better Care for Diabetes Management
More than 1 million children and adults in the United States have type 1 diabetes, according to the American Diabetes Association. The Centers for Disease Control and Prevention (CDC) note that about 5%Trusted Source of all people who...
International Diabetes Closed Loop (IDCL) Study Showcases Positive Results for Artificial Pancreas System
A multicenter clinical trial has found that a new artificial pancreas system—which automatically monitors and regulates blood glucose levels—has found that the new system was more effective than existing treatments at controlling blood glucose levels in people with...
Benaroya Research Institute Praises the Results of a Teplizumab-based Clinical Trial as it can Delay Onset of Type 1 Diabetes
A new global study reveals that an immunotherapy drug called teplizumab can delay the onset of Type 1 diabetes for at least two years in high-risk kids and adults, according to the results of a recent study with 28 research sites. Recently reported in WNDU 16...
Artificial Pancreas System Created by Researchers at the Indian Institute of Science Designed to Treat Type 1 Diabetes
Set for clinical trial next year, this first-of-its-kind innovation will design algorithms specific to the Indian gene and an indigenous insulin pump, which, researchers said, would make the system act like a pancreas. Collaboration Indian Institute of Science (IISc)...
Artificial Pancreas Evidences Potential in Clinical Trial
A clinical trial primarily funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has found an artificial pancreas system could effectively control blood glucose in patients with type I diabetes. The closed-loop system, Control-IQ,...
Association of Gluten Intake in First 5 Years of Life with Incidence of Celiac Disease Autoimmunity & Risk
The TEDDY (The Environmental Determinants of Diabetes in the Young) study is looking for the cause of type 1 diabetes mellitus (T1DM). A prospective observational birth cohort study designed to identify environmental triggers of type 1 diabetes and celiac disease,...
Harvard’s Doug Melton’s On a Mission to Cure Type 1 Diabetes—And Nature Is His Guide
Harvard researcher Doug Melton is on a mission to cure type 1 diabetes. He retooled his own lab to pursue this mission when both of his children developed the disease. For nearly a century, treating diabetes has remained pretty much the same—an injection of insulin to...
Johns Hopkins & Team of Researchers, & IBM Identify Immune Cell Linked to Type 1 Diabetes
Johns Hopkins and four collaborating institutions have found an existence of a long-doubted “X-cell” a “rogue hybrid” immune system cell that may play a key role in the development of type 1 diabetes. They have published their findings in the journal Cell. What did...
Regeneration of Insulin Producing Cells in Type 1 Diabetes: Uppsala Univ. Hospital ReGenerate-1
The Swedish Medical Products Agency has approved a new treatment arm with Remygen® and Alprazolam in Phase I/II ReGenerate-1 clinical trial led by Uppsala University Hospital and path-breaking investigator Professor Per-Ola Carlsson. The Study: ReGenerate-1 Uppsala...
EC Approves Dapagliflozin Thanks in Part to University of Buffalo Investigative Efforts
Ellen Goldbaum reports from the University News that the European Commission’s recent approval for dapagliflozin in patients with Type 1 diabetes was thinks in large part to innovative research conducted by the University of Buffalo’s (UB) Paresh Dandona, MD, SUNY...
Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injection Regimens in Children/Youth at Type 1 Diagnosis
As reported in the BMJ, the researchers sought to compare the efficacy, safety, and cost utility of continuous subcutaneous insulin infusion (CSII) with multiple daily injection (MDI) regimens during the first year following diagnosis of type 1 diabetes in children...
Oxfordshire Hosting the CLOuD Study Involving Artificial Pancreas Clinical Trial
Oxford’s John Radcliffe Hospital is hosting a ground-breaking study studying how to make the management of type 1 diabetes in newly diagnosed children a lot less stressful. Called the Closed Loop from Onset in Type 1 Diabetes (CLOuD) study, an insulin pump is...